Trials / Completed
CompletedNCT03535883
The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
The Safety of Thoracentesis, Tunneled Pleural Catheter (Pleurx), and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants (NOAC).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 590 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
Detailed description
The research component of this study simply observes and documents the outcomes of these procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this will be compared to their post-procedural (next day) hematocrit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Novel Oral Anti-Coagulants | Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.) |
Timeline
- Start date
- 2017-10-30
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2018-05-24
- Last updated
- 2023-10-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03535883. Inclusion in this directory is not an endorsement.